Literature DB >> 19350207

Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.

Carl Wibom1, Lina Mörén, Mads Aarhus, Per Morten Knappskog, Morten Lund-Johansen, Henrik Antti, A Tommy Bergenheim.   

Abstract

Meningiomas of WHO grade I can usually be cured by surgical resection. However, some tumors may, despite their benign appearance, display invasive growth behavior. These tumors constitute a difficult clinical problem to handle. By histology alone, bone invasive meningiomas may be indistinguishable from their noninvasive counterparts. In this study we have examined the protein spectra in a series of meningiomas in search of protein expression patterns that may distinguish between bone invasive and noninvasive meningiomas. Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI). Multivariate statistical methods were applied for data analyses. Comparing the protein spectra from invasive and noninvasive fibrous meningioma we found 22 peaks whose intensities were significantly different between the two groups (P < 0.001). Based on the expression pattern of these peaks we were able to perfectly separate the two entities (area under ROC curve = 1.0). In meningothelial meningioma the same comparison yielded six significantly differentially expressed peaks (P < 0.001), which to a large degree separated the invasive from noninvasive tissue (area under ROC curve = 0.873). By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I. A possibility for early identification of invasive grade I meningiomas may have a strong influence on the follow-up policy and the issue of early or late radiotherapy.

Entities:  

Mesh:

Year:  2009        PMID: 19350207     DOI: 10.1007/s11060-009-9865-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

1.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification.

Authors:  Haleem J Issaq; Timothy D Veenstra; Thomas P Conrads; Donna Felschow
Journal:  Biochem Biophys Res Commun       Date:  2002-04-05       Impact factor: 3.575

2.  A multivariate screening strategy for investigating metabolic effects of strenuous physical exercise in human serum.

Authors:  Elin Pohjanen; Elin Thysell; Pär Jonsson; Caroline Eklund; Anders Silfver; Inga-Britt Carlsson; Krister Lundgren; Thomas Moritz; Michael B Svensson; Henrik Antti
Journal:  J Proteome Res       Date:  2007-04-12       Impact factor: 4.466

3.  Comparative proteomic profiles of meningioma subtypes.

Authors:  Hiroaki Okamoto; Jie Li; Alexander O Vortmeyer; Howard Jaffe; Youn-Soo Lee; Sven Gläsker; Tae-Sung Sohn; Weifen Zeng; Barbara Ikejiri; Martin A Proescholdt; Christina Mayer; Robert J Weil; Edward H Oldfield; Zhengping Zhuang
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

4.  Proteomic studies on low- and high-grade human brain astrocytomas.

Authors:  Federico Odreman; Marco Vindigni; Marlen Lujardo Gonzales; Benedetta Niccolini; Giovanni Candiano; Bruno Zanotti; Miran Skrap; Stefano Pizzolitto; Giorgio Stanta; Alessandro Vindigni
Journal:  J Proteome Res       Date:  2005 May-Jun       Impact factor: 4.466

5.  Biomarker discovery: a proteomic approach for brain cancer profiling.

Authors:  Ashraf A Khalil; Peter James
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

6.  Proteomic profiling: a novel method for differential diagnosis?

Authors:  Sven Gläsker; Russell R Lonser; Hiroaki Okamoto; Jie Li; Howard Jaffee; Edward H Oldfield; Zhengping Zhuang; Alexander O Vortmeyer
Journal:  Cancer Biol Ther       Date:  2007-03-06       Impact factor: 4.742

7.  Can recurrence of meningiomas be predicted?

Authors:  Jean-Pierre Kalala; Dominique Benoit; Leo De Ridder
Journal:  Anticancer Res       Date:  2004 Jul-Aug       Impact factor: 2.480

8.  Management of bone-invasive, hyperostotic sphenoid wing meningiomas.

Authors:  Kerem Bikmaz; Robert Mrak; Ossama Al-Mefty
Journal:  J Neurosurg       Date:  2007-11       Impact factor: 5.115

9.  Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.

Authors:  M B Gretzer; D W Chan; C L van Rootselaar; J M Rosenzweig; S Dalrymple; L A Mangold; A W Partin; R W Veltri
Journal:  Prostate       Date:  2004-09-01       Impact factor: 4.104

10.  Radiosurgery as definitive management of intracranial meningiomas.

Authors:  Douglas Kondziolka; David Mathieu; L Dade Lunsford; Juan J Martin; Ricky Madhok; Ajay Niranjan; John C Flickinger
Journal:  Neurosurgery       Date:  2008-01       Impact factor: 4.654

View more
  9 in total

Review 1.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

2.  Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma.

Authors:  Joshua W Osbun; Philip D Tatman; Sumanpreet Kaur; Carolina Parada; Tina Busald; Luis Gonzalez-Cuyar; Min Shi; Donald E Born; Jing Zhang; Manuel Ferreira
Journal:  J Neurol Surg B Skull Base       Date:  2017-04-26

3.  Anatomic location is a risk factor for atypical and malignant meningiomas.

Authors:  Ari J Kane; Michael E Sughrue; Martin J Rutkowski; Gopal Shangari; Shanna Fang; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 4.  Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways.

Authors:  A Herrmann; J Ooi; S Launay; J L Searcy; R F Deighton; J McCulloch; I R Whittle
Journal:  J Neurooncol       Date:  2011-01-11       Impact factor: 4.130

Review 5.  Meningiomas and Proteomics: Focus on New Potential Biomarkers and Molecular Pathways.

Authors:  Rosaria Viola Abbritti; Francesca Polito; Maria Cucinotta; Claudio Lo Giudice; Maria Caffo; Chiara Tomasello; Antonino Germanò; Mohammed Aguennouz
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

6.  Quantitative proteomic analysis of meningiomas for the identification of surrogate protein markers.

Authors:  Samridhi Sharma; Sandipan Ray; Aliasgar Moiyadi; Epari Sridhar; Sanjeeva Srivastava
Journal:  Sci Rep       Date:  2014-11-21       Impact factor: 4.379

Review 7.  Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives.

Authors:  Hajime Takase; Tetsuya Yamamoto
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 8.  Multi-Omics Analysis in Initiation and Progression of Meningiomas: From Pathogenesis to Diagnosis.

Authors:  Jiachen Liu; Congcong Xia; Gaiqing Wang
Journal:  Front Oncol       Date:  2020-08-28       Impact factor: 6.244

Review 9.  Advances in MALDI mass spectrometry in clinical diagnostic applications.

Authors:  Eddy W Y Ng; Melody Y M Wong; Terence C W Poon
Journal:  Top Curr Chem       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.